OncoMatch/Clinical Trials/NCT06280105

A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib

Is NCT06280105 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Cadonilimab+regorafenib for hepatocellular carcinoma.

Phase 2RecruitingMeng Chao Hepatobiliary Hospital of Fujian Medical UniversityNCT06280105Data as of May 2026

Treatment: Cadonilimab+regorafenib — To evaluate the efficacy and safety of cadonilimab combined with Regorafenib in patients with hepatocellular carcinoma who failed camrelizumab plus apatinib.

Check if I qualify

Extracted eligibility criteria

Cancer type

Hepatocellular Carcinoma

Disease stage

Required: Stage INTERMEDIATE

intermediate or advanced hepatocellular carcinoma

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Min 1 prior line

Must have received: anti-PD-1 therapy plus VEGFR inhibitor (camrelizumab, apatinib) — combination

Have progressed on the combination treatment of camrelizumab and apatinib for HCC

Cannot have received: liver transplantation

Have a history of liver transplantation

Lab requirements

Blood counts

Neutrophils ≥ 1.5×10^9/L; Platelet count ≥ 75×10^9/L; Hemoglobin ≥ 90g/L

Kidney function

Serum creatinine ≤ 1.5x ULN or creatinine clearance ≥ 50 ml/min (Cockcroft-Gault formula); urine protein < 2+; if urine protein ≥ 2+, 24-hour urine protein quantification ≤ 1g

Liver function

Child-Pugh Class A; Total bilirubin (TBIL) ≤ 3x ULN; AST or ALT ≤ 10x ULN

The function of vital organs meets the following requirements... (see criteria 9 for details)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify